

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>NELSEN ROBERT</u> (Last) (First) (Middle) 8755 W. HIGGINS ROAD, SUITE 1025 (Street) CHICAGO IL 60631 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Vir Biotechnology, Inc. [VIR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/12/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/12/2022		J ⁽¹⁾		217,781	D	\$0	7,586,037	I	See footnote ⁽²⁾
Common Stock	08/12/2022		J ⁽¹⁾		282,219	D	\$0	9,830,626	I	See footnote ⁽³⁾
Common Stock	08/12/2022		J ⁽¹⁾⁽⁴⁾		27,489	A	\$0	322,723 ⁽⁵⁾	D	
Common Stock	08/12/2022		J ⁽¹⁾⁽⁴⁾		1,684	A	\$0	18,747 ⁽⁵⁾	I	See footnote ⁽⁵⁾
Common Stock	08/15/2022		J ⁽¹⁾		217,781	D	\$0	7,368,256	I	See footnote ⁽²⁾
Common Stock	08/15/2022		J ⁽¹⁾		282,219	D	\$0	9,548,407	I	See footnote ⁽³⁾
Common Stock	08/15/2022		J ⁽¹⁾⁽⁴⁾		27,489	A	\$0	350,212 ⁽⁵⁾	D	
Common Stock	08/15/2022		J ⁽¹⁾⁽⁴⁾		1,684	A	\$0	20,431 ⁽⁵⁾	I	See footnote ⁽⁵⁾
Common Stock	08/16/2022		J ⁽¹⁾		217,781	D	\$0	7,150,475	I	See footnote ⁽²⁾
Common Stock	08/16/2022		J ⁽¹⁾		282,219	D	\$0	9,266,188	I	See footnote ⁽³⁾
Common Stock	08/16/2022		J ⁽¹⁾⁽⁴⁾		27,489	A	\$0	377,701 ⁽⁵⁾	D	
Common Stock	08/16/2022		J ⁽¹⁾⁽⁴⁾		1,684	A	\$0	22,115 ⁽⁵⁾	I	See footnote ⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Explanation of Responses:

- Distribution of Common Stock held by a limited partnership to its partners for no consideration.
- The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.
- The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.
- Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.
- Shares held by a trust for the benefit of family members of the Reporting Person.

By: Robert Nelsen, Managing
Director, By: /s/ Mark 08/16/2022
McDonnell, as Attorney-in-
Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.